Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)114.40
  • Today's Change0.65 / 0.57%
  • Shares traded257.86k
  • 1 Year change+42.36%
  • Beta0.5746
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

  • Revenue in EUR (TTM)5.25bn
  • Net income in EUR343.00m
  • Incorporated--
  • Employees9.08k
  • Location
    Ucb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
  • Phone+32 25599999
  • Fax+32 25599900
  • Websitehttps://www.ucb.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eurofins Scientific SE6.51bn516.50m11.40bn61.80k22.632.2310.071.752.611.3032.9226.440.621336.204.79105,417.605.417.496.709.3620.9323.788.7111.231.388.430.433219.28-2.9411.49-21.5310.918.5811.66
Sandoz Group AG-102.80bn-102.80bn12.03bn23.85k------------------------------------------------7.23---90.92------
BioMerieux SA3.67bn357.60m12.10bn13.84k33.963.2223.563.293.013.0130.8531.760.70361.975.00--6.189.307.8812.3155.9956.518.7812.381.19--0.121519.012.398.70-20.956.878.3619.42
Genmab A/S2.21bn583.51m18.48bn2.20k31.554.31--8.3666.0566.05249.95483.850.5037--3.097,474,592.0013.3117.4314.2518.5955.82--26.4235.8713.32--0.0238--13.5740.35-20.1824.21-4.66--
argenx SE1.14bn-273.53m21.79bn1.15k--5.73--19.17-4.77-4.7719.9464.170.31950.43733.72990,282.20-7.69-17.65-8.49-19.7990.39---24.06-97.729.01--0.0049--198.56117.2558.42--122.32--
UCB SA5.25bn343.00m22.25bn9.08k64.982.4221.524.241.761.7626.9147.300.33451.764.63578,223.102.185.032.676.2867.5072.216.5312.660.92243.140.252936.44-4.802.54-18.33-15.41-1.512.36
Bayer AG47.64bn-2.94bn27.93bn99.72k--0.84833.740.5863-2.99-2.9948.4933.520.39511.434.85477,693.20-2.44-1.79-3.34-2.3858.5459.02-6.18-4.800.80153.400.5764---6.115.33-170.87--1.19-47.66
Data as of Mar 28 2024. Currency figures normalised to Ucb SA's reporting currency: Euro EUR

Institutional shareholders

18.53%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 17 Nov 202312.75m6.56%
Fidelity Management & Research Co. LLCas of 07 Mar 20245.86m3.01%
The Vanguard Group, Inc.as of 07 Mar 20244.48m2.30%
Norges Bank Investment Managementas of 31 Dec 20233.52m1.81%
BlackRock Fund Advisorsas of 07 Mar 20242.69m1.38%
Schroder Investment Management Ltd.as of 31 Dec 20231.73m0.89%
BlackRock Advisors (UK) Ltd.as of 07 Mar 20241.52m0.78%
Artisan Partners LPas of 31 Dec 20231.28m0.66%
Amundi Asset Management SA (Investment Management)as of 06 Mar 20241.27m0.65%
FMR Investment Management (UK) Ltd.as of 31 Jan 2024961.34k0.49%
More ▼
Data from 31 Dec 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.